Literature DB >> 7730216

Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori.

G Cederbrant1, G Kahlmeter, C Schalén, C Kamme.   

Abstract

The in-vitro activities of clarithromycin, 14-OH clarithromycin, erythromycin, amoxycillin, metronidazole and omeprazole against Helicobacter pylori were determined at pH 7.2 and 5.5. At pH 5.5 the activities of clarithromycin and erythromycin decreased approximately 16 times while 14-OH clarithromycin was less influenced. Chequerboard titration indicated that the combined activity of clarithromycin and the other compounds was additive.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7730216     DOI： 10.1093/jac/34.6.1025

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  16 in total

1.  In vitro activities of a new ketolide, ABT-773, alone and in combination with amoxicillin, metronidazole, or tetracycline against Helicobacter pylori.

Authors:  S L Pendland; J L Prause; M M Neuhauser; N Boyea; J M Hackleman; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori.

Authors:  Margareta Svensson; Lennart E Nilsson; Magnus Ström; Maud Nilsson; Mikael Sörberg
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

3.  The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.

Authors:  Morris O Makobongo; Hanan Gancz; Beth M Carpenter; Dennis P McDaniel; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

4.  Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.

Authors:  Takeshi Hagiwara; Mototsugu Kato; Tomonori Anbo; Akimichi Imamura; Toshihiro Suga; Takumi Uchida; Akira Fujinaga; Manabu Nakagawa; Soichi Nakagawa; Yuichi Shimizu; Jyunji Yamamoto; Hiroshi Takeda; Masahiro Asaka
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

5.  In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.

Authors:  T Alarcón; D Domingo; I Sánchez; F Díaz de Rojas; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

6.  CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.

Authors:  T Sakai; N Aoyama; T Kita; T Sakaeda; K Nishiguchi; Y Nishitora; T Hohda; D Sirasaka; T Tamura; Y Tanigawara; M Kasuga; K Okumura
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

7.  Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Jing Xu; Susumu Tazuma; Yoko Horikawa; Masuo Nakamura
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

8.  CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.

Authors:  T Kita; Y Tanigawara; N Aoyama; T Hohda; Y Saijoh; F Komada; T Sakaeda; K Okumura; T Sakai; M Kasuga
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

9.  In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.

Authors:  J M Meyer; S Ryu; S L Pendland; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

10.  Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates.

Authors:  Seung Bae Yoon; Jae Myung Park; Jong-Yul Lee; Myong Ki Baeg; Chul-Hyun Lim; Jin Soo Kim; Yu Kyung Cho; In Seok Lee; Sang Woo Kim; Myung-Gyu Choi
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.